γ-secretase inhibitors in solid tumor malignancies

Drugs of the Future

Volumn 36, Issue 9, 2011, Pages 677-689

  Arcaroli, J J ^a   Dasari, A ^a   Messersmith, W A ^a   Jimeno, Antonio ^a,b  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA SECRETASE INHIBITOR; MK 07502; MK 0752; NOTCH RECEPTOR; PF 03084014; RO 4929097; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ABDOMINAL CRAMP; ANOREXIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESEARCH; CARCINOGENESIS; CONSTIPATION; DIARRHEA; DRUG RESEARCH; DRUG TARGETING; FATIGUE; HUMAN; HYPOKALEMIA; HYPOPHOSPHATEMIA; LYMPHOCYTOPENIA; NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRURITUS; RASH; REVIEW; SIDE EFFECT; SOLID TUMOR; VOMITING;

EID: 84952979146     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.036.09.1678340     Document Type: Review

References (119)

1. Hu, Q.D., Ang, B.T., Karsak, M. et al. F3/contactin acts as a functional ligand for Notch during oligodendrocyte maturation. Cell 2003, 115(2): 163-75. (Pubitemid 37329580)
2. Hayward, P., Brennan, K., Sanders, P., Balayo, T., DasGupta, R., Perrimon, N., Martinez Arias, A. Notch modulates Wnt signalling by associating with armadillo/beta-catenin and regulating its transcriptional activity. Development 2005, 132(8): 1819-30. (Pubitemid 40691772)
3. Gustafsson, M.V., Zheng, X., Pereira, T. et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 2005, 9(5): 617-28. (Pubitemid 41555144)
4. Sade, H., Krishna, S., Sarin, A. The anti-apoptotic effect of Notch-1 requires p56lck-dependent, Akt/PKB-mediated signaling in T cells. J Biol Chem 2004, 279(4): 2937-44. (Pubitemid 38114286)
5. Blaumueller, C.M., Qi, H., Zagouras, P., Artavanis-Tsakonas, S. Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell 1997, 90(2): 281-91. (Pubitemid 27329713)
6. Cordle, J., Johnson, S., Tay, J.Z. et al. A conserved face of the Jagged/Serrate DSL domain is involved in Notch trans-activation and cisinhibition. Nat Struct Mol Biol 2008, 15(8): 849-57.
7. Raya, A., Kawakami, Y., Rodriguez-Esteban, C. et al. Notch activity acts as a sensor for extracellular calcium during vertebrate left-right determination. Nature 2004, 427(6970): 121-8. (Pubitemid 38094947)
8. Bolos, V., Blanco, M., Medina, V., Aparicio, G., Diaz-Prado, S., Grande, E. Notch signalling in cancer stem cells. Clin Transl Oncol 2009, 11(1): 11-9.
9. Weng, A.P., Ferrando, A.A., Lee, W. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306(5694): 269-71. (Pubitemid 39336870)
10. Friedmann, D.R., Wilson, J.J., Kovall, R.A. RAM-induced allostery facilitates assembly of a notch pathway active transcription complex. J Biol Chem 2008, 283(21): 14781-91.
11. Ehebauer, M.T., Chirgadze, D.Y., Hayward, P., Martinez Arias, A., Blundell, T.L. High-resolution crystal structure of the human Notch 1 ankyrin domain. Biochem J 2005, 392(Pt. 1): 13-20. (Pubitemid 41689396)
12. Nam, Y., Sliz, P., Song, L., Aster, J.C., Blacklow, S.C. Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell 2006, 124(5): 973-83. (Pubitemid 43344237)
13. Kopan, R., Ilagan, M.X. The canonical Notch signaling pathway: Unfolding the activation mechanism. Cell 2009, 137(2): 216-33.
14. Allenspach, E.J., Maillard, I., Aster, J.C., Pear, W.S. Notch signaling in cancer. Cancer Biol Ther 2002, 1(5): 466-76.
15. D'Souza, B., Miyamoto, A., Weinmaster, G. The many facets of Notch ligands. Oncogene 2008, 27(38): 5148-67.
16. Shimizu, K., Chiba, S., Kumano, K. et al. Mouse jagged1 physically interacts with notch2 and other notch receptors. Assessment by quantitative methods. J Biol Chem 1999, 274(46): 32961-9. (Pubitemid 129535335)
17. Fiuza, U.M., Arias, A.M. Cell and molecular biology of Notch. J Endocrinol 2007, 194(3): 459-74. (Pubitemid 47471215)
18. Zolkiewska, A. ADAM proteases: Ligand processing and modulation of the Notch pathway. Cell Mol Life Sci 2008, 65(13): 2056-68.
19. Mumm, J.S., Kopan, R. Notch signaling: From the outside in. Dev Biol 2000, 228(2): 151-65. (Pubitemid 32011983)
20. Selkoe, D.J., Wolfe, M.S. Presenilin: Running with scissors in the membrane. Cell 2007, 131(2): 215-21. (Pubitemid 47576152)
21. Wolfe, M.S., Kopan, R. Intramembrane proteolysis: Theme and variations. Science 2004, 305(5687): 1119-23. (Pubitemid 39100316)
22. Bray, S.J. Notch signalling: A simple pathway becomes complex. Nat Rev Mol Cell Biol 2006, 7(9): 678-89. (Pubitemid 44268213)
23. Edbauer, D., Winkler, E., Regula, J.T., Pesold, B., Steiner, H., Haass, C. Reconstitution of gamma-secretase activity. Nat Cell Biol 2003, 5(5): 486-8.
24. Li, H., Wolfe, M.S., Selkoe, D.J. Toward structural elucidation of the gamma-secretase complex. Structure 2009, 17(3): 326-34.
25. Kaether, C., Haass, C., Steiner, H. Assembly, trafficking and function of gamma-secretase. Neurodegener Dis 2006, 3(4-5): 275-83.
26. Chen, F., Hasegawa, H., Schmitt-Ulms, G. et al. TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilonsecretase activity. Nature 2006, 440(7088): 1208-12.
27. Zhang, Y.W., Luo, W.J., Wang, H. et al. Nicastrin is critical for stability and trafficking but not association of other presenilin/gamma- secretase components. J Biol Chem 2005, 280(17): 17020-6. (Pubitemid 41389164)
28. Watanabe, N., Tomita, T., Sato, C., Kitamura, T., Morohashi, Y., Iwatsubo, T. Pen-2 is incorporated into the gamma-secretase complex through binding to transmembrane domain 4 of presenilin 1. J Biol Chem 2005, 280(51): 41967-75. (Pubitemid 43023165)
29. Prokop, S., Shirotani, K., Edbauer, D., Haass, C., Steiner, H. Requirement of PEN-2 for stabilization of the presenilin N-/C-terminal fragment heterodimer within the gamma-secretase complex. J Biol Chem 2004, 279(22): 23255-61. (Pubitemid 38685633)
30. Lee, S.F., Shah, S., Yu, C. et al. A conserved GXXXG motif in APH-1 is critical for assembly and activity of the gamma-secretase complex. J Biol Chem 2004, 279(6): 4144-52. (Pubitemid 38198999)
31. Jeffries, S., Robbins, D.J., Capobianco, A.J. Characterization of a highmolecular- weight Notch complex in the nucleus of Notch(ic)-transformed RKE cells and in a human T-cell leukemia cell line. Mol Cell Biol 2002, 22(11): 3927-41. (Pubitemid 34525231)
32. Bailey, A.M., Posakony, J.W. Suppressor of hairless directly activates transcription of enhancer of split complex genes in response to Notch receptor activity. Genes Dev 1995, 9(21): 2609-22. (Pubitemid 3001579)
33. Davis, R.L., Turner, D.L. Vertebrate hairy and enhancer of split related proteins: Transcriptional repressors regulating cellular differentiation and embryonic patterning. Oncogene 2001, 20(58): 8342-57. (Pubitemid 34121905)
34. Rangarajan, A., Talora, C., Okuyama, R. et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J 2001, 20(13): 3427-36. (Pubitemid 32634350)
35. Iso, T., Kedes, L., Hamamori, Y. HES and HERP families: Multiple effectors of the Notch signaling pathway. J Cell Physiol 2003, 194(3): 237-55. (Pubitemid 36176887)
36. Iso, T., Sartorelli, V., Poizat, C., Iezzi, S., Wu, H.Y., Chung, G., Kedes, L., Hamamori, Y. HERP, a novel heterodimer partner of HES/E(spl) in Notch signaling. Mol Cell Biol 2001, 21(17): 6080-9. (Pubitemid 32737822)
37. Rones, M.S., Woda, J., Mercola, M., McLaughlin, K.A. Isolation and characterization of Xenopus Hey-1: a downstream mediator of Notch signaling. Dev Dyn 2002, 225(4): 554-60. (Pubitemid 35429737)
38. Buas, M.F., Kabak, S., Kadesch, T. The Notch effector Hey1 associates with myogenic target genes to repress myogenesis. J Biol Chem 2010, 285(2): 1249-58.
39. Artavanis-Tsakonas, S., Rand, M.D., Lake, R.J. Notch signaling: Cell fate control and signal integration in development. Science 1999, 284(5415): 770-6. (Pubitemid 29291335)
40. Lammert, E., Brown, J., Melton, D.A. Notch gene expression during pancreatic organogenesis. Mech Dev 2000, 94(1-2): 199-203. (Pubitemid 30332401)
41. Milner, L.A., Bigas, A. Notch as a mediator of cell fate determination in hematopoiesis: Evidence and speculation. Blood 1999, 93(8): 2431-48. (Pubitemid 29181173)
42. Callahan, R., Egan, S.E. Notch signaling in mammary development and oncogenesis. J Mammary Gland Biol Neoplasia 2004, 9(2): 145-63. (Pubitemid 39177500)
43. Karsan, A. The role of notch in modeling and maintaining the vasculature. Can J Physiol Pharmacol 2005, 83(1): 14-23. (Pubitemid 40754771)
44. Yoon, K., Gaiano, N. Notch signaling in the mammalian central nervous system: Insights from mouse mutants. Nat Neurosci 2005, 8(6): 709-15. (Pubitemid 43085834)
45. Radtke, F., Raj, K. The role of Notch in tumorigenesis: Oncogene or tumour suppressor? Nat Rev Cancer 2003, 3(10): 756-67. (Pubitemid 37328814)
46. van Es, J.H., van Gijn, M.E., Riccio, O. et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005, 435(7044): 959-63. (Pubitemid 40896322)
47. Chitnis, A., Henrique, D., Lewis, J., Ish-Horowicz, D., Kintner, C. Primary neurogenesis in Xenopus embryos regulated by a homologue of the Drosophila neurogenic gene delta. Nature 1995, 375(6534): 761-6.
48. Henrique, D., Hirsinger, E., Adam, J., Le Roux, I., Pourquie, O., Ish- Horowicz, D., Lewis, J. Maintenance of neuroepithelial progenitor cells by Delta-Notch signalling in the embryonic chick retina. Curr Biol 1997, 7(9): 661-70. (Pubitemid 27408864)
49. Lai, E.C. Notch signaling: Control of cell communication and cell fate. Development 2004, 131(5): 965-73. (Pubitemid 38380451)
50. Lewis, J. Notch signalling and the control of cell fate choices in vertebrates. Semin Cell Dev Biol 1998, 9(6): 583-9. (Pubitemid 128647238)
51. de Celis, J.F., Bray, S. Feed-back mechanisms affecting Notch activation at the dorsoventral boundary in the Drosophila wing. Development 1997, 124(17): 3241-51. (Pubitemid 27440439)
52. Huppert, S.S., Jacobsen, T.L., Muskavitch, M.A. Feedback regulation is central to Delta-Notch signalling required for Drosophila wing vein morphogenesis. Development 1997, 124(17): 3283-91. (Pubitemid 27440443)
53. Fortini, M.E. Notch signaling: The core pathway and its posttranslational regulation. Dev Cell 2009, 16(5): 633-47.
54. Miyamoto, Y., Maitra, A., Ghosh, B. et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003, 3(6): 565-76. (Pubitemid 36808651)
55. Santagata, S., Demichelis, F., Riva, A. et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 2004, 64(19): 6854-7. (Pubitemid 39330990)
56. Gray, G.E., Mann, R.S., Mitsiadis, E. et al. Human ligands of the Notch receptor. Am J Pathol 1999, 154(3): 785-94. (Pubitemid 29122597)
57. Cuevas, I.C., Slocum, A.L., Jun, P. Meningioma transcript profiles reveal deregulated Notch signaling pathway. Cancer Res 2005, 65(12): 5070-5. (Pubitemid 40827315)
58. Purow, B.W., Haque, R.M., Noel, M.W. et al. Expression of Notch-1 and its ligands, delta-like-1 and jagged-1, is critical for glioma cell survival and proliferation. Cancer Res 2005, 65(6): 2353-63. (Pubitemid 40490146)
59. Zagouras, P., Stifani, S., Blaumueller, C.M., Carcangiu, M.L., Artavanis- Tsakonas, S. Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc Natl Acad Sci U S A 1995, 92(14): 6414-8.
60. Nickoloff, B.J., Osborne, B.A., Miele, L. Notch signaling as a therapeutic target in cancer: A new approach to the development of cell fate modifying agents. Oncogene 2003, 22(42): 6598-608. (Pubitemid 37372340)
61. Fan, X., Mikolaenko, I., Elhassan, I. et al. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 2004, 64(21): 7787-93. (Pubitemid 39446911)
62. Bolos, V., Grego-Bessa, J., de la Pompa, J.L. Notch signaling in development and cancer. Endocr Rev 2007, 28(3): 339-63. (Pubitemid 46984831)
63. Murata, K., Hattori, M., Hirai, N. et al. Hes1 directly controls cell proliferation through the transcriptional repression of p27Kip1. Mol Cell Biol 2005, 25(10): 4262-71. (Pubitemid 40617671)
64. Oswald, F., Liptay, S., Adler, G., Schmid, R.M. NF-kappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa. Mol Cell Biol 1998, 18(4): 2077-88. (Pubitemid 28152657)
65. Rangarajan, A., Syal, R., Selvarajah, S., Chakrabarti, O., Sarin, A., Krishna, S. Activated Notch1 signaling cooperates with papillomavirus oncogenes in transformation and generates resistance to apoptosis on matrix withdrawal through PKB/Akt. Virology 2001, 286(1): 23-30. (Pubitemid 32675462)
66. Fitzgerald, K., Harrington, A., Leder, P. Ras pathway signals are required for notch-mediated oncogenesis. Oncogene 2000, 19(37): 4191-8.
67. Mittal, S., Subramanyam, D., Dey, D., Kumar, R.V., Rangarajan, A. Cooperation of Notch and Ras/MAPK signaling pathways in human breast carcinogenesis. Mol Cancer 2009, 8: 128.
68. Thelu, J., Rossio, P., Favier, B. Notch signalling is linked to epidermal cell differentiation level in basal cell carcinoma, psoriasis and wound healing. BMC Dermatol 2002, 2: 7.
69. Nicolas, M., Wolfer, A., Raj, K. et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 2003, 33(3): 416-21. (Pubitemid 36278861)
70. Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100(7): 3983-8. (Pubitemid 36418143)
71. Singh, S.K., Hawkins, C., Clarke, I.D. et al. Identification of human brain tumour initiating cells. Nature 2004, 432(7015): 396-401. (Pubitemid 39551674)
72. O'Brien, C.A., Pollett, A., Gallinger, S., Dick, J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445(7123): 106-10. (Pubitemid 46067310)
73. Li, C., Heidt, D.G., Dalerba, P. et al. Identification of pancreatic cancer stem cells. Cancer Res 2007, 67(3): 1030-7.
74. Schatton, T., Murphy, G.F., Frank, N.Y. et al. Identification of cells initiating human melanomas. Nature 2008, 451(7176): 345-9.
75. Pardal, R., Clarke, M.F., Morrison, S.J. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003, 3(12): 895-902. (Pubitemid 37500174)
76. Dalerba, P., Dylla, S.J., Park, I.K. et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007, 104(24): 10158-63. (Pubitemid 47175279)
77. Huang, E.H., Hynes, M.J., Zhang, T. et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009, 69(8): 3382-9.
78. Corti, S., Locatelli, F., Papadimitriou, D. et al. Identification of a primitive brain-derived neural stem cell population based on aldehyde dehydrogenase activity. Stem Cells 2006, 24(4): 975-85. (Pubitemid 44464730)
79. Jiang, F., Qiu, Q., Khanna, A. et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009, 7(3): 330-8.
80. Ma, S., Chan, K.W., Lee, T.K., Tang, K.H., Wo, J.Y., Zheng, B.J., Guan, X.Y. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res 2008, 6(7): 1146-53.
81. Harrison, H., Farnie, G., Howell, S.J. et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 2010, 70(2): 709-18.
82. Mullendore, M.E., Koorstra, J.B., Li, Y.M. et al. Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res 2009, 15(7): 2291-301.
83. Wang, J., Wakeman, T.P., Lathia, J.D. et al. Notch promotes radioresistance of glioma stem cells. Stem Cells 2010, 28(1): 17-28.
84. Fan, X., Khaki, L., Zhu, T.S. et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010, 28(1): 5-16.
85. Sikandar, S.S., Pate, K.T., Anderson, S., Dizon, D., Edwards, R.A., Waterman, M.L., Lipkin, S.M. NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res 2010, 70(4): 1469-78.
86. Hoey, T., Yen, W.C., Axelrod, F. et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009, 5(2): 168-77.
87. Anderson, L.M., Gibbons, G.H. Notch: A mastermind of vascular morphogenesis. J Clin Invest 2007, 117(2): 299-302. (Pubitemid 46203955)
88. Hellström, M., Phng, L.K., Hofmann, J.J. et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007, 445(7129): 776-80. (Pubitemid 46279716)
89. Jakobsson, L., Bentley, K., Gerhardt, H. VEGFRs and Notch: A dynamic collaboration in vascular patterning. Biochem Soc Trans 2009, 37(Pt. 6): 1233-6.
90. Noguera-Troise, I., Daly, C., Papadopoulos, N.J. et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Novartis Found Symp 2007, 283: 106-20; discussion 121-5, 238-41.
91. Pannuti, A., Foreman, K., Rizzo, P., Osipo, C., Golde, T., Osborne, B., Miele, L. Targeting Notch to target cancer stem cells. Clin Cancer Res 2010, 16(12): 3141-52.
92. Ranganathan, P., Weaver, K.L., Capobianco, A.J. Notch signalling in solid tumours: A little bit of everything but not all the time. Nat Rev Cancer 2011, 11(5): 338-51.
93. Rizzo, P., Osipo, C., Foreman, K., Golde, T., Osborne, B., Miele, L. Rational targeting of Notch signaling in cancer. Oncogene 2008, 27(38): 5124-31.
94. Han, J., Hendzel, M.J., Allalunis-Turner, J. Notch signaling as a therapeutic target for breast cancer treatment? Breast Cancer Res 2011, 13(3): 210.
95. Wang, Z., Ahmad, A., Li, Y., Azmi, A.S., Miele, L., Sarkar, F.H. Targeting notch to eradicate pancreatic cancer stem cells for cancer therapy. Anticancer Res 2011, 31(4): 1105-13.
96. Takebe, N., Harris, P.J., Warren, R.Q., Ivy, S.P. Targeting cancer stem cells by inhibiting Wnt, Notch, and hedgehog pathways. Nat Rev Clin Oncol 2011, 8(2): 97-106.
97. Al-Hussaini, H., Subramanyam, D., Reedijk, M., Sridhar, S.S. Notch signaling pathway as a therapeutic target in breast cancer. Mol Cancer Ther 2011, 10(1): 9-15.
98. Ristorcelli, E., Lombardo, D. Targeting Notch signaling in pancreatic cancer. Expert Opin Ther Targets 2010, 14(5): 541-52.
99. Dovey, H.F., John, V., Anderson, J.P. et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 2011, 76(1): 173-81.
100. Schor, N.F. What the halted phase III gamma-secretase inhibitor trial may (or may not) be telling us. Ann Neurol 2011, 69(2): 237-9.
101. Imbimbo, B.P., Giardina, G.A. γ-Secretase inhibitors and modulators for the treatment of Alzheimer's disease: Disappointments and hopes. Curr Top Med Chem 2011, 11(12): 1555-70.
102. Luistro, L., He, W., Smith, M. et al. Preclinical profile of a potent gammasecretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res 2009, 69(19): 7672-80.
103. th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 8546.
104. Berghtold, G., Dantas Barbosa, C. et al. NOTCH1 inhibition by the gamma-secretase inhibitor RO4929097 in pediatric glial tumors. J Clin Oncol [47th Annu Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2011] 2011 29(Suppl.): Abst 9555.
105. th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 2502.
106. He, W., Luistro, L., Carvajal, D. et al. High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the gamma-secretase inhibitor, RO4929097. Mol Oncol 2011, 5(3): 292-301.
107. th Annu Meet Am Soc Clin Oncol (ASCO) (June 3- 7, Chicago) 2011] 2011 29(Suppl.): Abst e14058.
108. Lanz, T.A., Wood, K.M., Richter, K.E. et al. Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014. J Pharmacol Exp Ther 2010, 334(1): 269-77.
109. Wei, P., Walls, M., Qiu, M. et al. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther 2010, 9(6): 1618-28.
110. Real, P.J., Tosello, V., Palomero, T. et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 2009, 15(1): 50-8.
111. th Annu Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2011] 2011 29(Suppl.): Abst 3100.
112. nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006, Abst 10574.
113. th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 9502.
114. Eriksen, J.L., Sagi, S.A., Smith, T.E. et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 2003, 112(3): 440-9. (Pubitemid 38063773)
115. in t' Veld, B.A., Ruitenberg, A., Hofman, A. et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001, 345(21): 1515-21.
116. Stewart, W.F., Kawas, C., Corrada, M., Metter, E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997, 48(3): 626-32. (Pubitemid 27120096)
117. Zandi, P.P., Anthony, J.C., Hayden, K.M., Mehta, K., Mayer, L., Breitner, J.C. Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County Study. Neurology 2002, 59(6): 880-6.
118. Green, R.C., Schneider, L.S., Amato, D.A., Beelen, A.P., Wilcock, G., Swabb, E.A., Zavitz, K.H. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial. JAMA 2009, 302(23): 2557-64.
119. nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006, Abst 6585.